Pre-implantation genetic diagnosis (PGD) is at an unprecedented ethical crossroads: while France legally prohibits embryo selection to eliminate those with Down’s syndrome, considering it “eugenic drift”, in Silicon Valley the opposite practice is spreading: selecting embryos with supposed genes for “higher intelligence”. Although effective in detecting serious monogenic diseases, this technique has no scientific basis when applied to complex traits such as intelligence, which depend on thousands of genes and environmental factors. Nevertheless, the appeal of “designing” the traits of future children drives a market that ignores both the technical limitations and the dignity of embryonic life, raising fundamental questions about eugenics, discrimination, and the intrinsic value of every human life from its earliest stages.

PGD in embryos conceived through in vitro fertilization (IVF) involves an invasive procedure in which one or two cells in the early stages of their development are biopsied, taking care not to affect their viability. The DNA or chromosomal complement of these cells is studied in order to detect any beneficial or negative traits related to their future development, after which it is a matter of deciding whether or not to implant the screened embryos. The selected embryos are transferred to the uterus at day 4-7, when the blastocyst stage is reached. PGD was first applied in 1985 to detect the presence of the sickle cell allele in the genome of a human embryo using a PCR test. Today, laser-assisted analysis methods, statistical technologies for comparative analysis, and software applications have been developed that make it easier to interpret the results, primarily aimed at detecting genes responsible for diseases determined by monogenic systems. Given the risks of affecting embryo viability, non-invasive methods have been tested, consisting of the analysis of free embryonic DNA in the embryo culture medium. So far, however, the results provided by this technology are limited due to contamination problems with extra-embryonic DNA, maternal DNA, mosaicism, etc.[1] 

As we mentioned in an article published on the Bioethics Observatory website in June 2024, although the capacity of PGD is real for a set of simple genetic systems — fundamentally for major chromosomal abnormalities and diseases that are determined by monogenic systems — it is not applicable to cases of complex diseases determined by polygenic systems, which involve multiple additive action genes distributed throughout the genome. This can be partially attributed to the fact that, in the vast majority of traits based on these systems, calculation of the so-called “polygenic risk” reveals few differences between adults, and even fewer among embryos derived from the same couple. Polygenic risk evaluates the probability that a person will develop a disease or trait determined by multiple genes and is based on the comparative analysis of DNA from thousands of people following large-scale genome-wide association studies (GWAS). To that end, the genomes of a large sample of people are compared to detect variants in the DNA (markers) common among those who present a certain trait.

The ostensible social appeal of choosing our children’s traits has led to the growth of companies that offer the application of PGD to meet this demand. Thus, on 20 June, the Bioethics Observatory published an article on the selection of embryos created through IVF using PGD to obtain children with a longer life expectancy, a trait with a certain polygenic component. This type of initiative has sparked intense ethical debate in which both the scientific data on the beginning of life and the real possibilities of analyzing certain traits must be taken into account, as well as the moral aspects concerning the value and dignity of human embryonic life.

News reports have recently emerged highlighting the importance of considering the ethical and scientific drawbacks of allowing rules or laws that would authorize the implementation of applications that take us back to the era of social eugenics in the early twentieth century when, following the advent of genetics, efforts were made to control birth rates and the notion of the perfect child was encouraged.

Negative eugenic drift. The elimination of carriers of chromosomal abnormalities

On 10 July this year, the Paris Court of Appeal upheld a February 2024 ruling by the Administrative Court of Montreuil, which declared the authorization issued in 2021 by the French National Agency for the Safety of Medicines and Health Products (ANSM) for the clinical trial DEVIT (Ethical Diagnosis of Individual and Transgenerational Variations) to be unlawful. This research aimed to select human embryos created through IVF in order to eliminate carriers of aneuploidies (PGD-A) or other chromosomal abnormalities, such as those that cause Down’s syndrome (trisomy 21), Patau syndrome (trisomy 13), and Edwards syndrome (trisomy 18).

It is important to note the legal efforts in support of a technology that disregards human dignity at the embryonic stage. Following intense parliamentary debates, the French legislature had denied such authorization during the last revision of the 2021 Bioethics Act. Back in 2020, the Minister of Health, Agnès Buzyn, spoke out against the drift towards eugenics, expressing concern about the fact that PGD implies a “right to select” among embryos. Despite the parliamentary decision, the ANSM authorized the DEVIT clinical trial. The Jérôme Lejeune Foundation appealed the matter before the Administrative Court of Appeal, citing the illegality of the trial authorization, and denounced the “eugenic drift” of this research. The appeal was joined by five adults with Down’s syndrome, alleging discrimination and considering that this procedure violates human dignity. The Paris Court of Appeal eventually ruled in favor of the Jérôme Lejeune Foundation, whose president, Jean-Marie Le Méné, stated that: “this decision is a new victory against the serious eugenic abuses within the reproductive technology industry… The Jérôme Lejeune Foundation remains committed to defending the dignity of every human being so that technological progress can be made in a way that respects our common humanity”.

However, the ANSM has appealed the ruling made by the Paris Administrative Court of Appeal, so pressure is expected to continue in parliamentary discussions for the legalization of PGD in the next review of the bioethics law, due in 2028.

Positive eugenic drift. Embryo selection in favor of higher intelligence

In contrast to the practice of discarding of embryos suspected of having chromosomal abnormalities or other diseases, there have been initiatives to apply PGD in favor of embryos that show “superior” genetic traits. This is the case of longer life expectancy or other traits considered beneficial, such as intelligence, height, or other physical characteristics. These types of traits may be only partially genetically determined or influenced by polygenic systems. Apart from the problems of achieving unerring accuracy in predicting these types of traits in embryos, the same ethical criticisms apply to the abuse of a technology that entails the discrimination and elimination of multiple human lives, even healthy ones, simply for not living up to expectations.

Recently, in the world of Silicon Valley, the leaders of this San Francisco Bay ecosystem, convinced that their unquestionable success in the development of artificial intelligence and computer technology is due to their genes, as well as their followers, entrepreneurs and wealthy individuals, are supporting the application of PGD to raise the intellectual quotient (IQ) of their own children, assuming a genetic basis for human intelligence. Behind this lies a clear economic interest from companies offering the service to clients who are convinced of the infallibility of predicting a trait that, in this case, may not emerge until years after birth.

Naturally, the success of this application depends on the relationship between intelligence and genes, as well as the ability to analyze DNA and detect the allelic differences responsible for the trait targeted for selection. As we shall see below, this belief is very questionable for complex traits, such as intelligence, height, or others dependent on polygenic systems in which educational and environmental factors play an important role.

The question of whether intelligence has a greater or lesser hereditary component has been much discussed, with responsibility attributed to both genes and the environment according to authors and schools. Evidence tells us that there are notable differences between school-age children and adults in the ability to create a work of art, to play a musical instrument proficiently, solve mathematical problems, play chess, etc.

“Intelligence tests” are traditionally applied to measure intelligence, and people are classified based on their so-called IQ. Although there are different ways of estimating it, what seems clear is that if it were heritable, intellectual capacity would be determined by polygenic systems, while not ruling out other non-genetic factors. In principle, no major genes have been described that determine clear phenotypic classes allowing people to be classified as intelligent or not intelligent. In contrast, the phenotypic classification of IQ tests shows a binomial distribution, in which the largest representation corresponds to people with an average IQ of between 90 and 110, with exceptional data below 65 (intellectual disability) or above 180 (high intelligence). Statistical analyses comparing IQ data and genomic differences for certain markers like SNPs (single nucleotide base polymorphisms) allow groups to be established. However, almost half the variations between intelligence levels among individuals could be attributed to hundreds or even thousands of differences in DNA that would contribute additively to the trait.[2,3] The next step would be to evaluate the differential DNA markers, and determine the relative value of their contribution to the overall trait.

The team led by geneticist Shai Carmi of the Hebrew University of Jerusalem calculated the expected increase in IQ and height in a sample of embryos by analyzing the DNA in order to choose those with the highest scores. This analysis was based on the genomic comparison of the offspring of 28 large families with an average of 10 children. Regarding height, the incidence of unknown environmental influences was determined, which could include factors such as diet and genes not represented in the polygenic score and that predominated over the molecular markers evaluated. The conclusions indicate that, whatever the results would have been, they would have been irrelevant if applied to embryos.[4]

Within the vast number of minor genes that add up their effects, researchers at the Institute of Psychiatry at King’s College London have identified one that seems to contribute significantly to intelligence. The study included the analysis of DNA samples, magnetic resonance, and intelligence tests from over 1,500 fourteen-year-olds. They found that that an allele of the NPTN gene contributed to the best results in the intelligence test. This gene indirectly affects the communication between brain cells by encoding a protein that acts in the process and that may also control the formation of the cerebral cortex, whose thickness is related to intellectual capacity. However, the NPTN gene can explain only 0.5% of the total variation in intelligence,[4] which, probably more than any other trait, is influenced by environmental, social, economic, and cultural factors; in short, education. However high the genetic determination of intelligence, it is doubtful that it would develop if not stimulated through effective learning and training. From this perspective, PGD is unlikely to deliver the intended results.

Bioethical aspects and future trend of PGD

Selecting a child based on their genetic profile is in practice an act of eugenics, whether it is to discard carriers of unwanted genes, or to select embryos according to desired traits. PGD involves directly discarding dozens of embryos for not meeting the requirements of a preconceived genetic design. It is a neoeugenic technique that allows the elimination of thousands of embryos each year in the clinics where it is carried out, ignoring the fact that, when an embryo is selected or eliminated, a human life in its early stage of development is being selected or eliminated.

The Catholic Church in the instruction Donum vitae (1987), ratified in Dignitas Personae (2008), denounces this fact by defending the right to life and physical integrity of every human being from conception to natural death. It is a good example of the contemplation of scientific data and ethical analysis, in stating that “The fruit of human generation from the first moment of its existence, i.e. from the constitution of the zygote, demands the unconditional respect that is morally due to the human being in his bodily and spiritual totality. The human being must be respected and treated as a person from the moment of conception and, therefore, from that very moment, the rights of the person must be recognised, principally the inviolable right of every innocent human being to life”.

Despite this, PGD is authorized by law in many Western countries under certain conditions. Spanish Law 14/2006 on assisted human reproduction allows PGD for certain cases, which contradicts international commitments signed by the Spanish government, such as the “Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine” or the “Oviedo Convention”, a treaty established by the Council of Europe and signed by Spain on 4 April 1997.

Despite this, the trend is to maintain and even expand the applications of genetic analysis in embryos for eugenic purposes. Polygenic risk scores are expected to improve over time as more effective comparative methods are developed, the environmental factors that influence them become better understood, and the type of markers to be used is refined. Even so, performing this type of testing on embryos is unethical, constitutes discrimination against individuals, and violates human dignity at its most vulnerable stage.

Nicolás Jouve

Professor Emeritus of Genetics at the University of Alcalá

Member of the Bioethics Observatory of the Catholic University of Valencia

 

References

[1] M. Vera–Rodriguez et al., Origin and composition of cell–free DNA in spent medium from human embryo culture during preimplantation development. Hum. Reprod. 2018. 33:745–756

[2] Davies G, Tenesa A, Payton A,… Deary IJ.   Genome-wide association studies establish that human intelligence is highly heritable and polygenic. Molecular Psychiatry. 2011. 16: 996-1005.

[4] Karavani E, Zuk O… Carmi S. Screening Human Embryos for Polygenic Traits Has Limited Utility. Cell. 2019. 27;179(6):1424-1435

[5] Deary IJ, Yang J, Davies G,.. Visscher PM. Genetic contributions to stability and change in intelligence from childhood to old age, Nature. 2012: 482: 212–215.

[4] Desrivières S, Lourdusamy A, Tao C, Schumann G; IMAGEN Consortium. Single nucleotide polymorphism in the neuroplastin locus associates with cortical thickness and intellectual ability in adolescents. Mol Psychiatry. 2015. 20(2):263-274.

Share This Story, Choose Your Platform!